J Korean Med Assoc.  2020 Jan;63(1):30-35. 10.5124/jkma.2020.63.1.30.

Drug-induced nephrotoxicity

• Bae E
• Lee TW
• Park DJ

• KMID: 2467983
• DOI: http://doi.org/10.5124/jkma.2020.63.1.30

Abstract

Drugs are a common cause of acute and chronic kidney disease and contribute to patient morbidity and increased healthcare utilization. Drug-induced nephrotoxicity is approximately 14% to 26% in adults and tends to increase among certain patients and/or with complex clinical conditions. Unfortunately, apart from conservative management, including drug withdrawal, no effective treatment is known for this condition. Therefore, in order to reduce the frequency of drug-induced nephrotoxicity, early recognition of renal toxicity and appropriate prevention strategies, such as understanding the exact mechanisms of renal injury, patient and drug-related risk factors, and preemptive measures are needed. In this review, we will present the mechanisms of drug-induced nephrotoxicity and general preventive strategies for clinical physicians.

Keyword

Glomerulus; Kidney tubules; Renal insufficiency; Pharmaceutical preparations; Toxicity

MeSH Terms

Adult
Delivery of Health Care
Humans
Kidney Tubules
Pharmaceutical Preparations
Renal Insufficiency
Renal Insufficiency, Chronic
Risk Factors
Pharmaceutical Preparations

Reference

1. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM. Program to Improve Care in Acute Renal Disease. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004; 66:1613–1621.

2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294:813–818.

3. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015; 41:1411–1423.

4. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta. 2005; 351:31–47.

5. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4:1275–1283.

6. Perazella MA. Drug-induced nephropathy: an update. Expert Opin Drug Saf. 2005; 4:689–706.

7. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci. 2003; 325:349–362.

8. Hoste EA, Kellum JA. Acute kidney injury: epidemiology and diagnostic criteria. Curr Opin Crit Care. 2006; 12:531–537.

9. Kohli HS, Bhaskaran MC, Muthukumar T, Thennarasu K, Sud K, Jha V, Gupta KL, Sakhuja V. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant. 2000; 15:212–217.

10. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005; 11:555–565.

11. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin Nephrol. 1997; 17:3–14.

12. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006; 2:80–91.

13. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999; 106:13S–24S.

14. Ahn GY, Bae SC. Strategies for the safe use of non-steroidal anti-inflammatory drugs. J Korean Med Assoc. 2018; 61:367–375.

15. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013; 19:3033–3042.

16. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf. 1999; 21:471–488.

17. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64:281–289.

18. Ko GJ. Contrast-induced nephropathy. Korean J Med. 2015; 88:375–381.

19. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001; 12:1164–1172.

20. Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010; 77:956–961.

21. Cho MK, Kang DY, Kang HR. Adverse drug reactions. J Korean Med Assoc. 2019; 62:472–479.

22. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60:804–817.

23. Baek JY, Kim EI, Kim YO, Choi YS, Suh JP, Kim JS, Yoon SA, Bang BK. A case of acyclovir induced acute interstitial nephritis. Korean J Nephrol. 2000; 19:1159–1162.

24. Han EJ, Kim SM, Lee HS, Jeon SC, Jung YJ, Yim H, Cho SW, Kim H, Shin GT. Entecavir-induced tubulointerstitial nephritis. Korean J Nephrol. 2010; 29:504–508.

25. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, Voss D. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006; 11:381–385.

26. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999; 106:459–465.

27. Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis: an overview for clinicians. Crit Care. 2005; 9:158–169.

28. Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. Curr Opin Pediatr. 2004; 16:206–210.

29. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001; 24:491–501.

30. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008; 51:491–503.

31. Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med. 2002; 69:289–296.

32. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004; 351:159–169.

33. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care. 2005; 11:533–536.

34. Kim SY. Preventing acute kidney injury induced by contrast medium. Korean J Nephrol. 2007; 26:657–659.

35. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006; 354:379–386.

36. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014; 7:457–468.

37. Bauer L. Creatinine clearance versus glomerular filtration rate for the use of renal drug dosing in patients with kidney dysfunction. Pharmacotherapy. 2005; 25:1286–1287.

38. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS. Chronic Kidney Disease Epidemiology Collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 2009; 54:33–42.

39. Kaufman J, Dhakal M, Patel B, Hamburger R. Community-acquired acute renal failure. Am J Kidney Dis. 1991; 17:191–198.

40. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289:1107–1116.

41. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008; 78:743–750.